Sunitinib specifically augments glucose-induced insulin secretion

Carlisle, 2016, Benefit, risk, and outcomes in drug development: a systematic review of sunitinib, J. Natl. Cancer Inst., 108, 10.1093/jnci/djv292 Faivre, 2007, Molecular basis for sunitinib efficacy and future clinical development, Nat. Rev. Drug Discov., 6, 734, 10.1038/nrd2380 Templeton, 2008, Remission of diabetes while on sunitinib treatment for renal cell carcinoma, Ann. Oncol., 19, 824, 10.1093/annonc/mdn047 Billemont, 2008, Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib, Br. J. Cancer, 99, 1380, 10.1038/sj.bjc.6604709 Huda, 2014, Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes, Diabetes Care, 37, e87, 10.2337/dc13-2132 Agostino, 2011, Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice, J. Oncol. Pharm. Pract., 17, 197, 10.1177/1078155210378913 Louvet, 2008, Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice, Proc. Natl. Acad. Sci. U. S. A., 105, 18895, 10.1073/pnas.0810246105 Tyrrell, 2014, Sunitinib and improved diabetes control, BMJ Case Rep., 2014, 10.1136/bcr-2014-207521 Leroith, 2008, Mechanisms of disease: using genetically altered mice to study concepts of type 2 diabetes, Nat. Clin. Pract. Endocrinol. Metab., 4, 164, 10.1038/ncpendmet0729 Jabs, 2008, Reduced insulin secretion and content in VEGF-a deficient mouse pancreatic islets, Exp. Clin. Endocrinol. Diabetes, 116, S46, 10.1055/s-2008-1081486 Welsh, 1990, Coexpression of the platelet-derived growth factor (PDGF) B chain and the PDGF beta receptor in isolated pancreatic islet cells stimulates DNA synthesis, Proc. Natl. Acad. Sci. U. S. A., 87, 5807, 10.1073/pnas.87.15.5807 Lammert, 2003, Role of VEGF-A in vascularization of pancreatic islets, Curr. Biol., 13, 1070, 10.1016/S0960-9822(03)00378-6 Brissova, 2006, Pancreatic islet production of vascular endothelial growth factor–a is essential for islet vascularization, revascularization, and function, Diabetes, 55, 2974, 10.2337/db06-0690 Kamba, 2006, VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, Am. J. Physiol. Heart Circ. Physiol., 290, H560, 10.1152/ajpheart.00133.2005 Shin, 2010, Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells, Biochem. Biophys. Res. Commun., 398, 205, 10.1016/j.bbrc.2010.06.060 Aguirre, 2010, Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor, Toxicol. Pathol., 38, 416, 10.1177/0192623310364027 Kawasaki, 1998, A family of cAMP-binding proteins that directly activate Rap1, Science, 282, 2275, 10.1126/science.282.5397.2275 Lochner, 2006, The many faces of H89: a review, Cardiovasc. Drug Rev., 24, 261, 10.1111/j.1527-3466.2006.00261.x Cheng, 2008, Epac and PKA: a tale of two intracellular cAMP receptors, Acta Biochim. Biophys. Sin. Shanghai, 40, 651, 10.1111/j.1745-7270.2008.00438.x Shen, 2012, IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination, FEBS Open Bio, 2, 1, 10.1016/j.fob.2011.12.001 Avram, 2008, IGF-1 protects against dexamethasone-induced cell death in insulin secreting INS-1 cells independent of AKT/PKB phosphorylation, Cell. Physiol. Biochem., 21, 455, 10.1159/000129638 Ullrich, 2014, IGF-1 and insulin-receptor signalling in insulin secreting cells: from function to survival, 659 Panse, 2015, Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion, Cell. Physiol. Biochem., 35, 1537, 10.1159/000373969 Ullrich, 1984, Islet cyclic AMP levels are not lowered during alpha 2-adrenergic inhibition of insulin release, J. Biol. Chem., 259, 4111, 10.1016/S0021-9258(17)43016-X Nolan, 2006, Fatty acid signaling in the beta-cell and insulin secretion, Diabetes, 55, S16, 10.2337/db06-S003 Latour, 2007, GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo, Diabetes, 56, 1087, 10.2337/db06-1532 Wagner, 2013, Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans, Diabetes, 62, 2106, 10.2337/db12-1249 Ferdaoussi, 2012, G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1, Diabetologia, 55, 2682, 10.1007/s00125-012-2650-x Schnell, 2007, Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40, Mol. Cell. Endocrinol., 263, 173, 10.1016/j.mce.2006.09.013 MacDonald, 2002, The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion, Diabetes, 51, S434, 10.2337/diabetes.51.2007.S434 Fehmann, 1995, The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets, Pancreas, 11, 196, 10.1097/00006676-199508000-00014 Kashima, 2001, Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion, J. Biol. Chem., 276, 46046, 10.1074/jbc.M108378200 Schwede, 2015, Rp-cAMPS prodrugs reveal the cAMP dependence of first-phase glucose-stimulated insulin secretion, Mol. Endocrinol., 29, 988, 10.1210/me.2014-1330 Meyer, 2011, PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation, Mol. Cell. Biol., 31, 2010, 10.1128/MCB.01006-10 Villalta, 2013, Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function, Diabetes, 62, 2870, 10.2337/db12-1619 Jewell, 2008, The tyrosine phosphorylation of Munc18c induces a switch in binding specificity from syntaxin 4 to Doc2beta, J. Biol. Chem., 283, 21734, 10.1074/jbc.M710445200 Bakke, 2013, Regulation of the SNARE-interacting protein Munc18c tyrosine phosphorylation in adipocytes by protein-tyrosine phosphatase 1B, Cell Commun. Signal, 11, 57, 10.1186/1478-811X-11-57 Hennige, 2003, Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes, J. Clin. Invest., 112, 1521, 10.1172/JCI18581 Hagerkvist, 2007, Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning, FASEB J., 21, 618, 10.1096/fj.06-6910com Mokhtari, 2011, Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro, PLoS One, 6, 10.1371/journal.pone.0024831 Hagerkvist, 2006, Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro, Cell Biol. Int., 30, 1013, 10.1016/j.cellbi.2006.08.006 Sanchez, 2013, Sunitinib enhances neuronal survival in vitro via NF-kappaB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase, J. Neuroinflammation, 10, 93, 10.1186/1742-2094-10-93 Krishnamurthy, 2007, Wang R: c-Kit in early onset of diabetes: a morphological and functional analysis of pancreatic beta-cells in c-KitW-v mutant mice, Endocrinology, 148, 5520, 10.1210/en.2007-0387 Rainer, 2012, Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes, BJU Int., 110, 1455, 10.1111/j.1464-410X.2012.11134.x Mooney, 2015, Effects of acute and chronic sunitinib treatment on cardiac function and calcium/calmodulin-dependent protein kinase II, Br. J. Pharmacol., 10